Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Rhea-AI Summary
Optimi Health (NASDAQ: OPTH), a commercial-stage manufacturer of regulated psychedelic drug products, completed a production run of a naturally derived psilocybin extract measuring about 6% psilocybin, its highest-purity botanical extract to date.
The extract will support Australian treatment-resistant depression prescriptions, upcoming European clinical research, and ongoing product development, while aggregate Scheme data to December 2025 report no serious adverse events.
Positive
- Completion of 6% psilocybin botanical extract, highest-purity produced by the company to date
- Naturally derived extract supports Australian 5 mg psilocybin capsule supply for treatment-resistant depression
- Expected GMP-grade psilocybin material supply for sponsor-led clinical studies in Europe
- No serious adverse events reported in Australia's Authorised Prescriber Scheme as of December 2025
- Cultivation improvements using more than 200 mushroom genetics and refined extraction processes
Negative
- None.
News Market Reaction – OPTH
In the May 26 session, OPTH declined 2.39%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-05-21 | Equity offering | Negative | -6.3% | Oversubscribed US$15M Nasdaq uplisting offering with new shares and warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history, but the recent capital raise was followed by a negative price reaction, suggesting sensitivity to financing events.
In the last week, Optimi Health completed an oversubscribed underwritten public offering of 2,400,000 shares at US$6.25, raising US$15 million in gross proceeds tied to its uplisting to the Nasdaq Capital Market. Shares reacted negatively, falling 6.25% over the next day. Today’s news instead highlights an operational milestone: a higher-purity, naturally derived psilocybin extract and ongoing supply into Australian and European channels, shifting focus from financing to execution.
Key Terms
treatment-resistant depression medical
authorised prescriber scheme regulatory
gmp-grade regulatory
psilocybin-assisted therapy medical
treatment-resistant depression ("trd") medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a production run of naturally derived psilocybin extract measuring approximately
The milestone reflects sustained gains across Optimi's cultivation program. Drawing on a proprietary library of more than 200 distinct mushroom genetics maintained at the Company's facilities, Optimi has selectively advanced cultivars demonstrating increasingly elevated psilocybin content. Those cultivation improvements, combined with refinements to the Company's extraction process, have produced a botanical extract substantially more concentrated than prior production cycles while maintaining its naturally derived profile.
A portion of the completed extract has been earmarked to support upcoming clinical research programs in Europe, where Optimi is expected to supply GMP-grade finished material into sponsor-led studies. Consistent with the Company's role as a regulated manufacturer rather than a drug-development sponsor, Optimi's contribution is the supply of psilocybin-containing finished drug products.
Remaining biomass from the psilocybin production cycle will be retained at Optimi's facilities for ongoing product development, formulation refinement, and future regulated supply initiatives as international access pathways continue to expand.
The milestone also reinforces Optimi's commercial supply in Australia, where the Company's naturally derived 5 mg psilocybin capsules are being prescribed for treatment-resistant depression ("TRD") under the Therapeutic Goods Administration's Authorised Prescriber Scheme. The higher-purity extract strengthens the material base supporting that supply. Optimi remains among a small number of commercial-stage companies worldwide whose psilocybin drug products are reaching patients through reimbursed treatment pathways, with eligible Australian patients accessing psilocybin-assisted therapy for TRD supported by established reimbursement initiatives.
Aggregated data published in connection with Australia's Authorised Prescriber Scheme, under which Optimi has supplied psilocybin finished products since September 2025, indicate that no serious adverse events have been reported among patients treated with psilocybin under the Scheme as of December 2025.
"Higher purity from naturally derived material is a manufacturing achievement," said Dane Stevens, CEO and Co-Founder of Optimi Health. "We have spent years building a cultivation and extraction platform that gets stronger with every cycle. Reaching
About Optimi Health Corp.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.
Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
For more information, please visit www.optimihealth.ca.
For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are based on several assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, and other filings with the US Securities and Exchange Commission that we make from time to time which are available at www.sec.gov or in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298817